Neil Riordan, PhD will Present “Umbilical Cord Mesenchymal Stem Cells in the Treatment of Autoimmune Diseases” at the 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine at the Gaylord Palms Hotel in Orlando, Florida as…
Neil Riordan, PhD Presents at American Academy of Anti-Aging Medicine’s 22nd Annual World Congress on Anti-Aging, Regenerative and Aesthetic Medicine in Orlando, May 15
The dual effect of MSCs on tumour growth and tumour angiogenesis
Michelle Kéramidas, Florence de Fraipont, Anastassia Karageorgis, Anaïck Moisan, Virginie Persoons, Marie-Jeanne Richard, Jean-Luc Coll and Claire Rome
Abstract (provisional)
Introduction
Understanding the multiple biological functions played by human mesenchymal stem cells (hMSCs) as well as their development as therapeutics in regenerative medicine or in cancer treatment are major fields of research. Indeed, it has been established that hMSCs play a central role in the pathogenesis and progression of tumours, but their impact on tumour growth remains controversial.
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Methods
In this study, we investigated the influence of hMSCs on the growth of pre-established tumours. We engrafted nude mice with luciferase-positive mouse adenocarcinoma cells (TSA-Luc+) to obtain subcutaneous or lung tumours. When tumour presence was confirmed by non-invasive bioluminescence imaging, hMSCs were injected into the periphery of the SC tumours or delivered by systemic intravenous injection in mice bearing either SC tumours or lung metastasis.
Results
Regardless of the tumour model and mode of hMSC injection, hMSC administration was always associated with decreased tumour growth due to an inhibition of tumour cell proliferation, likely resulting from deep modifications of the tumour angiogenesis. Indeed, we established that although hMSCs can induce the formation of new blood vessels in a non-tumoural cellulose sponge model in mice, they do not modify the overall amount of haemoglobin delivered into the SC tumours or lung metastasis. We observed that these tumour vessels were reduced in number but were longer.
Conclusions
Our results suggest that hMSCs injection decreased solid tumour growth in mice and modified tumour vasculature, which confirms hMSCs could be interesting to use for the treatment of pre-established tumours.
Original Link: http://stemcellres.com/content/4/2/41/abstract
Liposuction method can adversely affect adipose tissue-derived stem cell yield and growth
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure which was published in Cytotherapy (vol. 8 issue 2, 2006, pages 166-177)states that:
“Ultrasound-assisted liposuction resulted in a lower frequency of proliferating adult stem cells, as well as a longer population doubling time of adult stem cells, compared with resection…”
Those seeking adipose stem cell therapy should ask their doctor if he or she is using ultrasound assisted liposuction to collect the fat sample.
*Stem Cell Institute does not use ultrasound assisted liposuction.
Adipose tissue-derived mesenchymal stem cell yield and growth characteristics are affected by the tissue-harvesting procedure
M.J. Oedayrajsingh-Varma1, S.M. van Ham2, M. Knippenberg3, M.N. Helder4, J. Klein-Nulend3, T.E. Schouten5, M.J.P.F. Ritt1, F.J. van Milligen, PhD5,
1 Department of Plastic Reconstructive and Hand Surgery, VU University Medical Center, Amsterdam, the Netherlands
2 Department of Immunopathology, Sanquin Research at CLB, Amsterdam, the Netherlands
3 Department of Oral Cell Biology, ACTA-Vrije Universiteit, Amsterdam, the Netherlands
4 Department of Orthopaedic Surgery, VU University Medical Center, Amsterdam, the Netherlands
5 Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
http://dx.doi.org/10.1080/14653240600621125, How to Cite or Link Using DOI
Permissions & Reprints
Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 3 of 5)
Mesenchymal stem cell homing to tissue damage, umbilical cord stem cells historically used for anti-aging, mesenchymal stem cells role in immune system modulation, inflammation reduction and stimulating tissue regeneration, donor stem cell safety and testing, the role of HLA matching in donated umbilical cord-derived stem cells, umbilical cord blood safety data and historical use in blood transfusions, allogeneic stem cell persistence in human mothers.
Neil Riordan PhD – Stem cell therapy for spinal cord injury (part 2 of 5)
Case studies of spinal cord injury patients treated with CD34+ and mesenchymal stem cells harvested from human umbilical cord Wharton’s jelly and cord blood, animal studies using mesenchymal stem cells, immunosuppression requirements in allogeneic stem cell treatments, intrathecal and intravenous administration of autologous bone marrow stem cells in spinal cord injury patients, and the role adult stem cell trophic factors in tissue regeneration.